Driver gene‑negative advanced‑stage lung adenocarcinoma is associated with a poor prognosis and insufficient treatment options. The present study aimed to evaluate the efficacy and safety profile of a programmed cell death protein 1/programmed death‑ligand 1 inhibitor plus bevacizumab and chemotherapy (PBC) regimen for the treatment of patients with driver gene‑negative advanced‑stage lung adenocarcinoma under real‑world clinical conditions. Data from 65 patients with advanced‑stage lung adenocarcinoma without sensitizing epidermal growth factor receptor, ALK receptor tyrosine kinase or ROS proto‑oncogene 1 receptor tyrosine kinase mutations who received a PBC regimen or only a BC regimen were reviewed in the present retrospective cohort study. The results revealed that the objective response rate was higher (70.4 vs. 47.4%; P=0.065) in the PBC group compared with that in the BC group, while not reaching statistical significance. Progression‑free survival (PFS) time was longer in the PBC group than in the BC group [median PFS: 10.8 months (95% confidence interval (CI), 7.2‑14.4) vs. 7.6 months (95% CI, 5.0‑10.2); P=0.016], while overall survival (OS) exhibited a non‑significant trend to be longer in the PBC group compared with that in the BC group [median OS: 20.6 months (95% CI, 16.8‑24.4) vs. 15.9 months (95% CI, 11.8‑20.0); P=0.115]. Following adjustment by multivariate Cox analysis, the PBC (vs. BC) regimen was found to be independently associated with an improved PFS time (P=0.045). The common adverse events in the PBC group were neutropenia, alopecia, leukopenia, nausea and vomiting, fatigue, anemia and peripheral neuropathy. Moreover, the incidence of each adverse event did not differ significantly between the PBC and BC groups. In conclusion, the present study demonstrated that the PBC regimen serves as a superior treatment option for patients with driver gene‑negative advanced‑stage lung adenocarcinoma; however, further verification of its efficacy is still required.

Related Articles